Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Reagents and methods for cancer detection, prognosis, and therapeutic monitoring

A technology for cancer treatment and cancer, which is applied in the field of diagnosing cancer, predicting cancer occurrence or recurrence and/or monitoring cancer treatment, and can solve problems such as metastatic disease that cannot be cured

Pending Publication Date: 2022-02-18
SANFORD HEALTH +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Only 5% of U.S. women develop metastatic basal cell carcinoma at first diagnosis; however, most BCa-related deaths are due to incurable metastatic disease rather than initial diagnosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Reagents and methods for cancer detection, prognosis, and therapeutic monitoring
  • Reagents and methods for cancer detection, prognosis, and therapeutic monitoring
  • Reagents and methods for cancer detection, prognosis, and therapeutic monitoring

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[1042] Example / Case Study 1

[1043] Serum samples from 200 newly diagnosed breast cancer patients were stained for ANA before starting any treatment. This patient population represented heterogeneity of disease, including 74% invasive, 26% in situ, 87% ductal, 11% lobular, 24% nodal involvement, 86% ER positive, 17% of HER-2-positive and 12% of triple-negative breast cancers. HEp-2 cells were seeded in 96-well tissue culture plates. Cells were fixed, permeabilized, and incubated with serum samples at an initial dilution of 1:40. Secondary antibody AlexaTM 488 goat anti-human IgG was added for pattern detection. Cells were imaged using a CellInsight CX7TM instrument. Positive samples diluted at 1:40 were further screened with 1:2 serial dilutions of 1:40, 1:80, 1:160, and 1:320. Staining patterns were scored independently by two scientists to ensure accuracy and reproducibility of pattern determination. Reference sera for each staining pattern were obtained from SLR Rese...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to View More

Abstract

Methods and related reagents are disclosed for diagnosing cancer, prognosing cancer occurrence or recurrence, and / or monitoring cancer therapy, involving contacting a bodily fluid sample from a subject at risk of having cancer or cancer recurrence, or from a subject that has been treated for cancer wl fit (a)one or more first antibody detection marker molecules that hind to human autoantibodies against at least one tumor associated antigen (TAA); and (fa) one or more second antibody detection marker molecules that bind to human autoantibodies against at least one extractable nuclear antigen (ENA).

Description

[0001] cross reference [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 859,264, filed June 10, 2019, which is hereby incorporated by reference in its entirety. [0003] Federal Funding Statement: [0004] This invention was made with Government Support No. P20GM103548 awarded by the National Institutes of Health and #1R44CA217447-01 awarded by the National Cancer Institute. The government has certain rights in this invention. [0005] Statement Regarding Sequence Listing [0006] This application contains a Sequence Listing submitted as an electronic text file "17-689-PCT_Sequence-Listing_ST25.txt" created on June 4, 2020, with a size (bytes) of 152kb. Pursuant to 37 CFR §1.52(e)(5), all information contained in this electronic document is incorporated by reference. Background technique [0007] The 5-year survival rate for women diagnosed with localized breast cancer (BCa) is 98.6%. Local stage survival dropped to 83.8% and long te...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/574G01N33/57415G01N2333/8125
Inventor 克里斯提·艾格兰德瑞克·伊万斯伊加帕纳特·蒂鲁帕蒂大卫·优尔马特·考斯图拉艾蒂安·格尼皮巴
Owner SANFORD HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com